Company Description
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction.
Our two most advanced candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors designed to inhibit the transmission of pain.
We are also advancing additional Nav1.8 candidates that can address alternative formulation and delivery approaches.
Beyond Nav1.8, we plan to explore other ion channel targets involved in pain transmission that offer complementary mechanisms of action, enabling potential use in multi-modal treatment to enhance pain relief or address diverse pain etiologies.
Our initial development efforts are focused on musculoskeletal pain, where we believe there is significant unmet need and an opportunity for differentiated clinical benefit utilizing a Nav1.8 mechanism.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Nima Farzan |
Contact Details
Address: 1300 Rancho Conejo Boulevard, Suite 305 Thousand Oaks, CA 91320 United States | |
| Phone | (805) 716-2927 |
| Website | latigobio.com |
Stock Details
| Ticker Symbol | LTGO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2056611 |
Key Executives
| Name | Position |
|---|---|
| Nima Farzan | Director, President and Chief Executive Officer |
| Neha Krishnamohan | Chief Financial Officer and Chief Business Officer |
| Neil Singla, M.D. | Chief Medical Officer |
| Timothy P. Walbert | Chair |
| Sara Bonstein | Director |
| Deborah Palestrant, Ph.D. | Director |
| Kevin Raidy | Director |
| Beth Seidenberg, M.D. | Director |
| Todd N. Smith | Director |
| James B. Tananbaum, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 5, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 18, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 27, 2026 | DRS | [Cover] Draft Registration Statement |
| Feb 13, 2025 | D | Notice of Exempt Offering of Securities |